Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Expansion of myeloid-derived suppressor cells from peripheral blood decreases after 4-week antiviral treatment in patients with chronic hepatitis C.

Liu Y, She LH, Wang XY, Zhang GL, Yan Y, Lin CS, Zhao ZX, Gao ZL.

Int J Clin Exp Med. 2014 Apr 15;7(4):998-1004. eCollection 2014.

2.

Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients.

Cai W, Qin A, Guo P, Yan D, Hu F, Yang Q, Xu M, Fu Y, Zhou J, Tang X.

J Clin Immunol. 2013 May;33(4):798-808. doi: 10.1007/s10875-012-9861-2. Epub 2013 Jan 26.

PMID:
23354838
3.

Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR ζ chain expression on CD8(+) T cells in chronic hepatitis C patients.

Zeng QL, Yang B, Sun HQ, Feng GH, Jin L, Zou ZS, Zhang Z, Zhang JY, Wang FS.

Mol Cells. 2014 Jan;37(1):66-73. doi: 10.14348/molcells.2014.2282. Epub 2014 Jan 27.

4.

[Effect of antiviral treatment on expression of programmed death 1 and programmed death ligand 1 on peripheral T lymphocytes in patients with chronic hepatitis C].

Cai RT, Shen L, Zhao W, Yang YF, Zhang YC.

Zhonghua Gan Zang Bing Za Zhi. 2013 Apr;21(4):261-6. doi: 10.3760/cma.j.issn.1007-3418.2013.04.006. Chinese.

PMID:
24021786
5.

Hepatitis C Virus Induces MDSCs-Like Monocytes through TLR2/PI3K/AKT/STAT3 Signaling.

Zhai N, Li H, Song H, Yang Y, Cui A, Li T, Niu J, Crispe IN, Su L, Tu Z.

PLoS One. 2017 Jan 23;12(1):e0170516. doi: 10.1371/journal.pone.0170516. eCollection 2017.

6.

[Dynamic changes in PD-1, TLR3, and TLR4 surface expression on peripheral blood mononuclear cells in chronic hepatitis C patients undergoing peg-IFNalpha-2a plus ribavirin combination therapy].

Zhang M, Jiang YF, Xiao XQ, Liu SF, Peng ML, Liu D, Gong GZ.

Zhonghua Gan Zang Bing Za Zhi. 2013 Mar;21(3):196-201. Chinese.

PMID:
23967741
7.

Clinical Significance of Myeloid-Derived Suppressor Cells in Human Immunodeficiency Virus-1/ Hepatitis C Virus-coinfected Patients.

Lei AH, Yang Q, Cai WP, Liu YF, Lan Y, Qin AP, Hu FY, Zhou J.

Scand J Immunol. 2016 Jun;83(6):438-44. doi: 10.1111/sji.12429.

8.

A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatment.

Soldevila B, Alonso N, Martínez-Arconada MJ, Morillas RM, Planas R, Sanmartí AM, Martínez-Cáceres EM.

J Viral Hepat. 2011 Jun;18(6):384-92. doi: 10.1111/j.1365-2893.2010.01317.x.

PMID:
20487258
9.

Monocyte-derived dendritic cells in children with chronic hepatitis C: correlation with interferon and ribavirin therapy.

Khedr MA, E Behairy B, Hussein ME, Marei AM, Nage SA, Zakaria HM.

Eur J Gastroenterol Hepatol. 2015 Oct;27(10):1170-4. doi: 10.1097/MEG.0000000000000422.

PMID:
26148246
10.

Circulating T follicular helper cells are associated with rapid virological response in chronic hepatitis C patients undergoing peginterferon therapy.

Zhang M, Zhang L, Li H, Chen Z, Luo A, Liu B, Chen M, Peng M, Ren H, Hu P.

Int Immunopharmacol. 2016 May;34:235-43. doi: 10.1016/j.intimp.2016.03.005. Epub 2016 Mar 10.

PMID:
26971227
11.

Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.

Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG; MErimepodib TRiple cOmbination Study Group.

Hepatology. 2009 Dec;50(6):1719-26. doi: 10.1002/hep.23204.

PMID:
19852040
12.

The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients.

Choi HS, Ha SY, Kim HM, Ahn SM, Kang MS, Kim KM, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Kang ES.

Oncotarget. 2016 Feb 16;7(7):7940-51. doi: 10.18632/oncotarget.6958.

13.

[Dynamic changes in programmed death-1 expression on the surface of T cells in chronic hepatitis C patients undergoing interferon therapy].

Dong RQ, Zhou DF, Han R, Zhou JY, Zhao CY, Zhen Z.

Zhonghua Gan Zang Bing Za Zhi. 2013 Dec;21(12):899-902. doi: 10.3760/cma.j.issn.1007-3418.2013.12.005. Chinese.

PMID:
24636290
14.

IFN-α-based treatment of patients with chronic HCV show increased levels of cells with myeloid-derived suppressor cell phenotype and of IDO and NOS.

Salem ML, Zidan AA, Attia M, El-Naggar RE, Nassef M, Abou El-Azm AR, El-Bate H, Yussif M, Galal S, Abo Senna M, El Demellawy M.

Immunopharmacol Immunotoxicol. 2017 Aug;39(4):188-198. doi: 10.1080/08923973.2017.1320670. Epub 2017 May 4.

PMID:
28472907
16.

Myeloid-derived suppressor cells suppress CD4⁺ and CD8⁺ T cell responses in autoimmune hepatitis.

Li H, Dai F, Peng Q, Gan H, Zheng J, Xia Y, Zhang W.

Mol Med Rep. 2015 Sep;12(3):3667-73. doi: 10.3892/mmr.2015.3791. Epub 2015 May 15.

PMID:
25998831
17.

Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment.

Elefsiniotis IS, Vezali E, Kamposioras K, Pantazis KD, Tontorova R, Ketikoglou I, Moulakakis A, Saroglou G.

World J Gastroenterol. 2006 Jul 21;12(27):4420-4.

18.

Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.

Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW.

Gastroenterology. 2002 Oct;123(4):1070-83.

PMID:
12360469
19.

Hepatitis C virus core protein triggers expansion and activation of CD4(+)CD25(+) regulatory T cells in chronic hepatitis C patients.

Zhai N, Chi X, Li T, Song H, Li H, Jin X, Crispe IN, Su L, Niu J, Tu Z.

Cell Mol Immunol. 2015 Nov;12(6):743-9. doi: 10.1038/cmi.2014.119. Epub 2014 Dec 22.

20.

Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection.

Peng G, Li S, Wu W, Sun Z, Chen Y, Chen Z.

Immunology. 2008 Jan;123(1):57-65. Epub 2007 Aug 31.

Supplemental Content

Support Center